JP2020513033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513033A5 JP2020513033A5 JP2020502549A JP2020502549A JP2020513033A5 JP 2020513033 A5 JP2020513033 A5 JP 2020513033A5 JP 2020502549 A JP2020502549 A JP 2020502549A JP 2020502549 A JP2020502549 A JP 2020502549A JP 2020513033 A5 JP2020513033 A5 JP 2020513033A5
- Authority
- JP
- Japan
- Prior art keywords
- activator
- mineral
- antagonist
- preparation according
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 103
- 239000011707 mineral Substances 0.000 claims description 103
- 239000012190 activator Substances 0.000 claims description 73
- 239000005557 antagonist Substances 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 40
- 239000011248 coating agent Substances 0.000 claims description 32
- 238000000576 coating method Methods 0.000 claims description 32
- 238000009472 formulation Methods 0.000 claims description 32
- 239000011859 microparticle Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000000589 Interleukin-1 Human genes 0.000 claims description 13
- 108010002352 Interleukin-1 Proteins 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 5
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 claims description 5
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 claims description 5
- 102100026015 Interleukin-1 family member 10 Human genes 0.000 claims description 5
- 108050004799 Interleukin-1 family member 10 Proteins 0.000 claims description 5
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 5
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 5
- 102100033500 Interleukin-33 Human genes 0.000 claims description 5
- 102100033474 Interleukin-36 alpha Human genes 0.000 claims description 5
- 108050004801 Interleukin-36 alpha Proteins 0.000 claims description 5
- 102100033503 Interleukin-36 gamma Human genes 0.000 claims description 5
- 101710195086 Interleukin-36 gamma Proteins 0.000 claims description 5
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 claims description 5
- 101710089409 Interleukin-36 receptor antagonist protein Proteins 0.000 claims description 5
- 102100033502 Interleukin-37 Human genes 0.000 claims description 5
- 229960002964 adalimumab Drugs 0.000 claims description 5
- 229960004238 anakinra Drugs 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 5
- 229960000403 etanercept Drugs 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 229960000598 infliximab Drugs 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 150000002739 metals Chemical class 0.000 claims description 5
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 102100033498 Interleukin-36 beta Human genes 0.000 claims description 2
- 108050003379 Interleukin-36 beta Proteins 0.000 claims description 2
- 229910052789 astatine Inorganic materials 0.000 claims description 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 239000011247 coating layer Substances 0.000 description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480710P | 2017-04-03 | 2017-04-03 | |
| US62/480,710 | 2017-04-03 | ||
| PCT/US2018/025913 WO2018187344A1 (en) | 2017-04-03 | 2018-04-03 | Mineral coated microparticles for sustained delivery of biologically active molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513033A JP2020513033A (ja) | 2020-04-30 |
| JP2020513033A5 true JP2020513033A5 (https=) | 2021-05-13 |
| JP7170031B2 JP7170031B2 (ja) | 2022-11-11 |
Family
ID=63712804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502549A Active JP7170031B2 (ja) | 2017-04-03 | 2018-04-03 | 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12465654B2 (https=) |
| EP (1) | EP3606512A4 (https=) |
| JP (1) | JP7170031B2 (https=) |
| KR (1) | KR20190130643A (https=) |
| CN (1) | CN110691588A (https=) |
| AU (1) | AU2018249816B2 (https=) |
| BR (1) | BR112019020373A2 (https=) |
| CA (1) | CA3058802A1 (https=) |
| IL (1) | IL269607A (https=) |
| WO (1) | WO2018187344A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190130643A (ko) | 2017-04-03 | 2019-11-22 | 위스콘신 얼럼나이 리서어치 화운데이션 | 생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자 |
| WO2022051247A1 (en) * | 2020-09-01 | 2022-03-10 | Dianomi Therapeutics, Inc. | Methods for treating or preventing inflammatory events |
| DE102020129648A1 (de) * | 2020-11-10 | 2022-05-12 | Leopold MTX GmbH | Pharmazeutische zusammensetzung |
| CN114917364A (zh) * | 2022-05-12 | 2022-08-19 | 云南大学附属医院 | 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法 |
| WO2024102801A2 (en) * | 2022-11-09 | 2024-05-16 | Wisconsin Alumni Research Foundation | Mineral-coated iron oxide microparticles and use of same including use for immunomodulation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| JP2003212756A (ja) * | 2002-01-21 | 2003-07-30 | Olympus Optical Co Ltd | 薬剤徐放剤 |
| EP1750746A1 (en) * | 2004-06-04 | 2007-02-14 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| US7655758B2 (en) * | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| CN104324362B (zh) * | 2005-09-14 | 2018-04-24 | 曼金德公司 | 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法 |
| WO2008041704A1 (fr) | 2006-10-02 | 2008-04-10 | National Institute For Materials Science | Préparation à libération contrôlée |
| US20100143439A1 (en) * | 2007-04-16 | 2010-06-10 | University Of Toledo | Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor |
| US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
| CN102014975A (zh) | 2008-02-29 | 2011-04-13 | 史密夫和内修有限公司 | 用于生物医学应用的梯度涂层 |
| US20100015049A1 (en) * | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| US11607391B2 (en) * | 2008-09-25 | 2023-03-21 | Trs Holdings Llc | Mineral-coated microspheres |
| US20160017368A1 (en) | 2013-02-19 | 2016-01-21 | Wisconsin Alumni Research Foundation | Inorganic coatings for the enhancement of chemical transfection |
| US11491261B2 (en) | 2015-03-03 | 2022-11-08 | Warsaw Orthopedic, Inc. | Coating scaffolds |
| EP4026568A1 (en) | 2015-04-17 | 2022-07-13 | CureVac Real Estate GmbH | Lyophilization of rna |
| KR20190130643A (ko) | 2017-04-03 | 2019-11-22 | 위스콘신 얼럼나이 리서어치 화운데이션 | 생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자 |
| EP3648750A4 (en) | 2017-07-05 | 2021-05-26 | Wisconsin Alumni Research Foundation | MINERAL-COATED MICROPARTICLE FOR THE SIMULTANEOUS ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES WITH NUCLEIC ACIDS TO IMPROVE THE GENERAL TRANSFER RESULTS |
| US11628227B2 (en) | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| EP3556728A1 (en) | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Organically modified mineral micro-particles, methods of preparing the same and uses thereof |
| US20190358344A1 (en) | 2018-05-23 | 2019-11-28 | Dianomi Therapeutics, Inc. | Mineral coated microparticles for sustained delivery of steroids |
| US20240325596A1 (en) | 2021-11-09 | 2024-10-03 | Wisconsin Alumni Research Foundation | Mineral-coated substrates for stabilization of rna-based therapeutic compositions |
-
2018
- 2018-04-03 KR KR1020197032235A patent/KR20190130643A/ko not_active Ceased
- 2018-04-03 WO PCT/US2018/025913 patent/WO2018187344A1/en not_active Ceased
- 2018-04-03 CA CA3058802A patent/CA3058802A1/en active Pending
- 2018-04-03 CN CN201880036493.0A patent/CN110691588A/zh active Pending
- 2018-04-03 AU AU2018249816A patent/AU2018249816B2/en active Active
- 2018-04-03 BR BR112019020373-7A patent/BR112019020373A2/pt active Search and Examination
- 2018-04-03 US US16/500,017 patent/US12465654B2/en active Active
- 2018-04-03 EP EP18780858.9A patent/EP3606512A4/en active Pending
- 2018-04-03 JP JP2020502549A patent/JP7170031B2/ja active Active
-
2019
- 2019-09-24 IL IL26960719A patent/IL269607A/en unknown
-
2025
- 2025-10-15 US US19/359,408 patent/US20260041786A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513033A5 (https=) | ||
| McCormack et al. | Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia | |
| JP2009522339A (ja) | 痛風または偽痛風の新規な治療法 | |
| JP2018505169A5 (https=) | ||
| JP6833816B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） | |
| HUP0402230A2 (hu) | Többszörös bevonattal ellátott gyógyszer dózisforma | |
| CN104661658A (zh) | 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素 | |
| US20260041786A1 (en) | Mineral coated microparticles for sustained delivery of biologically active molecules | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| CA2442478A1 (en) | Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation | |
| WO2008049842A3 (en) | Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders | |
| EP2413933B1 (en) | 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide for the treatment of migraine via the oral or intravenous route | |
| Pollenus et al. | CCR2 is dispensable for disease resolution but required for the restoration of leukocyte homeostasis upon experimental malaria-associated acute respiratory distress syndrome | |
| WO2019213686A1 (en) | Therapeutic compositions and uses therefor | |
| Rhoades et al. | RETRACTED: Potential role of lampalizumab for treatment of geographic atrophy | |
| JP2017031209A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| JP2014529606A5 (https=) | ||
| KR20130092617A (ko) | 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법 | |
| CN110461329A (zh) | 治疗血癌的PPARγ激动剂 | |
| US20200171022A1 (en) | Flt3 inhibitors for improving pain treatments by opioids | |
| CA2724982A1 (en) | Histamine binding protein | |
| WO2021004229A1 (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| Levin et al. | IL-17 and Other New Agents | |
| EP2344156B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
| CN1859901A (zh) | 含有加速作用开始的乙酰水杨酸的口服抗抑郁制剂 |